Use of population modeling to define rational monitoring of amiodarone hepatic effects

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 4, 2004, Pages 342-351

  Pollak, P Timothy ^a   Shafer, Steven L ^b  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMIODARONE; BILIRUBIN; DEETHYLAMIODARONE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER FUNCTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NONLINEAR SYSTEM; POPULATION MODEL; PRIORITY JOURNAL;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; BIOLOGICAL MARKERS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MASS SCREENING; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NONLINEAR DYNAMICS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TRANSAMINASES;

EID: 1842737789     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2003.12.008     Document Type: Article

References (42)

1. Pollak P.T. Oral amiodarone historical overview and development. Pharmacotherapy. 18:1998;121S-126S.
2. Gill J., Heel R.C., Fitton A. Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs. 43:1992;69-110.
3. Roy D., Talajic M., Dorian P., Connolly S., Eisenberg M.J., Green M., et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 342:2000;913-920.
4. Shinagawa K., Shiroshita-Takeshita A., Schram G., Nattel S. Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium insights into the mechanism of the superior efficacy of amiodarone. Circulation. 107:2003;1440-1446.
5. Cairns J.A., Connolly S.J., Roberts R., Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet. 349:1997;675-682.
6. Vorperian V.R., Havighurst T.C., Miller S., January C.T. Adverse effects of low dose amiodarone a meta-analysis. J Am Coll Cardiol. 30:1997;791-798.
7. Bunch C, Porter RS. Amiodarone [drug monograph]. In: Hutchison TA, Shahan DR, editors. DRUGDEX system. Greenwood Village (CO): MICROMEDEX; 2003
8. Pollak P.T., You Y.D. Monitoring of hepatic function during amiodarone therapy. Am J Cardiol. 91:2003;613-616.
9. Pollak P.T. A systematic review and critical comparison of internal standards for the routine liquid chromatographic assay of amiodarone and desethylamiodarone. Ther Drug Monit. 18:1996;168-178.
10. Sheiner L.B., Beal S.L. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 11:1983;303-319.
11. Rotmensch H.H., Belhassen B., Swanson B.N., Shoshani D., Spielman S.R., Greenspon A.J., et al. Steady-state serum amiodarone concentrations relationships with antiarrhythmic efficacy and toxicity. Ann Intern Med. 101:1984;462-469.
12. Lewis J.H., Mullick F., Ishak K.G., Ranard R.C., Ragsdale B., Perse R.M., et al. Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum Pathol. 21:1990;59-67.
13. Drent M., Cobben N.A., Van Dieijen-Visser M.P., Braat S.H., Wouters E.F. Serum lactate dehydrogenase activity indicator of the development of pneumonitis induced by amiodarone. Eur Heart J. 19:1998;969-970.
14. Macarri G., Feliciangeli G., Berdini V., Jezequel A.M., Benedetti A. Canalicular cholestasis due to amiodarone toxicity. A definite diagnosis obtained by electron microscopy. Ital J Gastroenterol. 27:1995;436-438.
15. Gilinsky N.H., Briscoe G.W., Kuo C.S. Fatal amiodarone hepatoxicity. Am J Gastroenterol. 83:1988;161-163.
16. Harris L., McKenna W.J., Rowland E., Krikler D.M. Side effects and possible contraindications of amiodarone use. Am Heart J. 106:1983;916-923.
17. Pollak P.T., Sharma A.D., Carruthers S.G. Relation of amiodarone hepatic and pulmonary toxicity to serum drug concentrations and superoxide dismutase activity. Am J Cardiol. 65:1990;1185-1191.
18. Sheiner L.B., Stanski D.R., Vozeh S., Miller R.D., Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics application to d-tubocurarine. Clin Pharmacol Ther. 25:1979;358-371.
19. Adams P.C., Holt D.W., Storey G.C., Morley A.R., Callaghan J., Campbell R.W. Amiodarone and its desethyl metabolite tissue distribution and morphologic changes during long-term therapy. Circulation. 72:1985;1064-1075.
20. Simon J.B., Manley P.N., Brien J.F., Armstrong P.W. Amiodarone hepatotoxicity simulating alcoholic liver disease. N Engl J Med. 311:1984;167-172.
21. Babany G., Mallat A., Zafrani E.S., Saint-Marc Girardin M.F., Carcone B., Dhumeaux D. Chronic liver disease after low daily doses of amiodarone. Report of three cases. J Hepatol. 3:1986;228-232.
22. Flaharty K.K., Chase S.L., Yaghsezian H.M., Rubin R. Hepatotoxicity associated with amiodarone therapy. Pharmacotherapy. 9:1989;39-44.
23. Sastri S.V., Diaz-Arias A.A., Marshall J.B. Can pancreatitis be associated with amiodarone hepatotoxicity? J Clin Gastroenterol. 12:1990;70-73.
24. Morelli S., Guido V., De Marzio P., Aguglia F., Balsano F. Early hepatitis during intravenous amiodarone administration. Cardiology. 78:1991;291-294.
25. Jeyamalar R., Pathmanathan R., Wong D., Kannan P. Hepatotoxicity of amiodarone. Ann Acad Med Singapore. 21:1992;838-840.
26. Richer M., Robert S. Fatal hepatotoxicity following oral administration of amiodarone. Ann Pharmacother. 29:1995;582-586.
27. Chang C.C., Petrelli M., Tomashefski J.F. Jr, McCullough A.J. Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug a case report and review of the literature. Arch Pathol Lab Med. 123:1999;251-256.
28. Latorre G., Lucas I., Herrero J.I., Sangro B., Quiroga J., Sola J.J., et al. Severe hepatotoxicity caused by amiodarone description of a case. Rev Med Univ Navarra. 43:1999;86-91. [in Spanish].
29. Jain D., Bowlus C.L., Anderson J.M., Robert M.E. Granular cells as a marker of early amiodarone hepatotoxicity. J Clin Gastroenterol. 31:2000;241-243.
30. Tagliamonte E., Cice G., Ducceschi V., Mayer M.S., Iacono A. Acute hepatitis following amiodarone administration. Minerva Cardioangiol. 45:1997;451-456. [in Italian].
31. Lee K.L., Tai Y.T. Long-term low-dose amiodarone therapy in the management of ventricular and supraventricular tachyarrhythmias efficacy and safety. Clin Cardiol. 20:1997;372-377.
32. Lewis J.H., Ranard R.C., Caruso A., Jackson L.K., Mullick F., Ishak K.G., et al. Amiodarone hepatotoxicity prevalence and clinicopathologic correlations among 104 patients. Hepatology. 9:1989;679-685.
33. Julian D.G., Camm A.J., Frangin G., Janse M.J., Munoz A., Schwartz P.J., et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet. 349:1997;667-674.
34. Pichler W.J., Schindler L., Staubli M., Stadler B.M., de Weck A.L. Anti-amiodarone antibodies detection and relationship to the development of side effects. Am J Med. 85:1988;197-202.
35. Breuer H.W., Bossek W., Haferland C., Schmidt M., Neumann H., Gruszka J. Amiodarone-induced severe hepatitis mediated by immunological mechanisms. Int J Clin Pharmacol Ther. 36:1998;350-352.
36. Berson A., De Beco V., Letteron P., Robin M.A., Moreau C., El Kahwaji J., et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology. 114:1998;764-774.
37. Gross S.A., Bandyopadhyay S., Klaunig J.E., Somani P. Amiodarone and desethylamiodarone toxicity in isolated hepatocytes in culture. Proc Soc Exp Biol Med. 190:1989;163-169.
38. Jessurun G.A., Boersma W.G., Crijns H.J. Amiodarone-induced pulmonary toxicity. Predisposing factors, clinical symptoms and treatment. Drug Saf. 18:1998;339-344.
39. Holt D.W., Tucker G.T., Jackson P.R., Storey G.C. Amiodarone pharmacokinetics. Am Heart J. 106:1983;840-847.
40. Pollak P.T., Bouillon T., Shafer S.L. Population pharmacokinetics of long-term oral amiodarone therapy. Clin Pharmacol Ther. 67:2000;642-652.
41. Meng X., Mojaverian P., Doedee M., Lin E., Weinryb I., Chiang S.T., et al. Bioavailability of amiodarone tablets administered with and without food in healthy subjects. Am J Cardiol. 87:2001;432-435.
42. Stelfox H.T., Ahmed S.B., Fiskio J., Bates D.W. Monitoring amiodarone's toxicities recommendations, evidence, and clinical practice. Clin Pharmacol Ther. 75:2004;110-122.